Grayline Clinical Drug Trials

Wichita Falls, Texas 76309-1608

0 studies enrolling now · 38 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Arthritis, Binge Eating Disorder, Bipolar I Depression, Central Nervous System Diseases, Chronic Pain, Cognition, Depression, Depressive Disorder, Major, Generalized Anxiety Disorder, Major Depressive Disorder

Studies at this site

• Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder — Completed
• Randomized Trial of Adult Participants With Generalized Anxiety Disorder — Completed
• Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease — Completed
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• Open Label Extension in Adults With Binge Eating Disorder (BED) — Completed
• SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder — Completed
• Tanezumab in Osteoarthritis of the Hip or Knee (2) — Completed
• Tanezumab In Osteoarthritis Of The Hip Or Knee — Stopped early
• Extension Study Of Tanezumab In Osteoarthritis — Stopped early
• Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study — Stopped early
• Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain — Completed
• Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) — Stopped early
• Tricaprilin in Mild to Moderate Alzheimer's Disease — Completed
• Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) — Stopped early
• A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder — Stopped early
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee — Completed
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) — Completed
• A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD — Completed
• Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil — Stopped early
• Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose — Completed
• Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects — Completed
• Major Depressive Disorder With Mixed Features - Extension — Completed
• Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients — Stopped early
• Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Stopped early
• Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed
• Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment — Completed
• An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type — Completed
• Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 — Completed
• Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder — Completed
• Major Depressive Disorder With Mixed Features — Withdrawn before enrolling
• A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression — Completed
• SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD) — Completed
• Mifepristone as Adjunctive Therapy in Alzheimer's Disease — Stopped early
• ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301) — Completed